An open label multicentric phase 1 study of selective cyclin dependent kinase inhibitor P276-00 [P-276] in patients with advanced refractory neoplasms

Trial Profile

An open label multicentric phase 1 study of selective cyclin dependent kinase inhibitor P276-00 [P-276] in patients with advanced refractory neoplasms

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jan 2013

At a glance

  • Drugs P 276 (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Sponsors Piramal Enterprises
  • Most Recent Events

    • 31 Dec 2008 Planned number of patients changed from 47 to 50 as reported by ClinicalTrials.gov.
    • 31 Dec 2008 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
    • 12 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top